Want to see ICUI full AI Analyst Report?
Revenue by Segment
Shows how sales split across ICU Medical’s businesses—such as infusion systems, IV disposables, oncology/chemotherapy products, and services—revealing which product lines drive growth and profit. A heavier weight in recurring consumables points to steadier, higher-margin cash flow, while reliance on capital equipment or a single segment increases sensitivity to hospital purchasing cycles, competitive shifts, or one-time contract wins and losses.Consumables and Infusion Systems are the operational engines — both delivering steady organic growth and supporting recent gross‑margin expansion (Infusion Systems hit a record pumps quarter) — while the sharp mid‑2025 collapse in Vital Care is largely an accounting/deconsolidation (IV Solutions) and portfolio‑pruning effect rather than pure organic collapse. Management expects tariff relief and efficiency gains to offset logistics and remediation costs, but FDA testing delays for new pumps and elevated near‑term capex/integration spend are the key execution risks to future upside and FCF/leverage targets.
Date | Consumables | Infusion Systems | Vital Care |
|---|---|---|---|
Jun 30, 2026 | $289.28M | $189.00M | $73.41M |
Mar 31, 2026 | $278.27M | $179.60M | $72.35M |
Dec 31, 2025 | $284.70M | $176.30M | $79.70M |
Sep 30, 2025 | $285.09M | $173.91M | $77.99M |
Jun 30, 2025 | $273.13M | $167.70M | $108.04M |
Mar 31, 2025 | $266.23M | $166.30M | $172.18M |
Dec 31, 2024 | $268.10M | $171.70M | $190.00M |
Sep 30, 2024 | $264.88M | $159.77M | $164.49M |
Jun 30, 2024 | $261.82M | $163.64M | $171.00M |
Mar 31, 2024 | $244.04M | $157.34M | $165.28M |